Insmed Incorporated (INSM)
- Previous Close
24.32 - Open
24.37 - Bid 24.10 x 500
- Ask 24.18 x 100
- Day's Range
23.55 - 25.15 - 52 Week Range
18.09 - 32.00 - Volume
2,644,532 - Avg. Volume
1,706,606 - Market Cap (intraday)
3.582B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-5.34 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
43.87
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
www.insmed.comRecent News: INSM
Performance Overview: INSM
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INSM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INSM
Valuation Measures
Market Cap
3.59B
Enterprise Value
4.01B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.11
Price/Book (mrq)
--
Enterprise Value/Revenue
13.14
Enterprise Value/EBITDA
-6.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-245.59%
Return on Assets (ttm)
-28.50%
Return on Equity (ttm)
--
Revenue (ttm)
305.21M
Net Income Avi to Common (ttm)
-749.57M
Diluted EPS (ttm)
-5.34
Balance Sheet and Cash Flow
Total Cash (mrq)
780.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-384.98M
Research Analysis: INSM
Company Insights: INSM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: INSM
Daily – Vickers Top Buyers & Sellers for 11/03/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/10/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/04/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.